A Pilot Randomized Tissue-Based Study Evaluating Anti-PD1 Antibody or Anti-PD1 + Bevacizumab or Anti-PD1 + Anti-CTLA-4 in Patients With Metastatic Renal Cell Carcinoma Who Are Eligible for Cytoreductive Nephrectomy, Metastasectomy or Post-Treatment Biopsy

Trial Profile

A Pilot Randomized Tissue-Based Study Evaluating Anti-PD1 Antibody or Anti-PD1 + Bevacizumab or Anti-PD1 + Anti-CTLA-4 in Patients With Metastatic Renal Cell Carcinoma Who Are Eligible for Cytoreductive Nephrectomy, Metastasectomy or Post-Treatment Biopsy

Recruiting
Phase of Trial: Phase 0

Latest Information Update: 08 Aug 2017

At a glance

  • Drugs Bevacizumab (Primary) ; Ipilimumab (Primary) ; Nivolumab (Primary)
  • Indications Renal cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 03 Aug 2017 Planned End Date changed from 1 Nov 2018 to 1 Nov 2019.
    • 03 Aug 2017 Planned primary completion date changed from 1 Nov 2018 to 1 Nov 2019.
    • 05 Apr 2017 Results (n=60) presented at the 108th Annual Meeting of the American Association for Cancer Research.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top